{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:35:03Z","timestamp":1781073303757,"version":"3.54.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003093","name":"ministry of education, malaysia","doi-asserted-by":"crossref","award":["FRGS\/1\/2020\/SKK06\/SYUC\/03\/1"],"award-info":[{"award-number":["FRGS\/1\/2020\/SKK06\/SYUC\/03\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010798","name":"sunway university","doi-asserted-by":"publisher","award":["IRG2021"],"award-info":[{"award-number":["IRG2021"]}],"id":[{"id":"10.13039\/501100010798","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00430-021-00726-1","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:04:01Z","timestamp":1642723441000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics"],"prefix":"10.1007","volume":"211","author":[{"given":"Mohd Ishtiaq","family":"Anasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-6291","authenticated-orcid":false,"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"726_CR1","first-page":"299","volume":"5","author":"NEA Murray","year":"2013","unstructured":"Murray NEA, Quam MB, Wilder-Smith A (2013) Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5:299","journal-title":"Clin Epidemiol"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2149\/tmh.2011-S10","volume":"39","author":"S Kalayanarooj","year":"2011","unstructured":"Kalayanarooj S (2011) Clinical manifestations and management of dengue\/DHF\/DSS. Trop Med Health 39:83","journal-title":"Trop Med Health"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"20130414","DOI":"10.1098\/rsif.2013.0414","volume":"10","author":"NG Reich","year":"2013","unstructured":"Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, Yoon I-K, Gibbons RV, Burke DS, Cummings DAT (2013) Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 10:20130414","journal-title":"J R Soc Interface"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science (New York, N.Y.) 328:745","journal-title":"Science (New York, N.Y.)"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1016\/j.vaccine.2016.06.082","volume":"34","author":"M Recker","year":"2016","unstructured":"Recker M, Vannice K, Hombach J, Jit M, Simmons CP (2016) Assessing dengue vaccination impact: model challenges and future directions. Vaccine 34:4461","journal-title":"Vaccine"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"e0155900","DOI":"10.1371\/journal.pone.0155900","volume":"11","author":"B Ramanathan","year":"2016","unstructured":"Ramanathan B, Poh CL, Kirk K, McBride WJH, Aaskov J, Grollo L (2016) Synthetic B-cell epitopes eliciting cross-neutralizing antibodies: strategies for future dengue vaccine. PLoS ONE 11:e0155900","journal-title":"PLoS ONE"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon I-K, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet (London, England) 384:1358","journal-title":"Lancet (London, England)"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garc\u00eda JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ram\u00edrez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cort\u00e9s Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113","journal-title":"N Engl J Med"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"e019368","DOI":"10.1136\/bmjopen-2017-019368","volume":"9","author":"BR Rosa","year":"2019","unstructured":"Rosa BR, da Cunha AJLA, Medronho RA (2019) Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2\u201317 years: systematic review and meta-analysis. BMJ Open 9:e019368","journal-title":"BMJ Open"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","volume":"2","author":"MG Guzman","year":"2016","unstructured":"Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB (2016) Dengue infection. Nat Rev Dis Primers 2:16055","journal-title":"Nat Rev Dis Primers"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1128\/jvi.69.11.7232-7243.1995","volume":"69","author":"B Falgout","year":"1995","unstructured":"Falgout B, Markoff L (1995) Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum. J Virol 69:7232","journal-title":"J Virol"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.00606-08","volume":"82","author":"GD Gromowski","year":"2008","unstructured":"Gromowski GD, Barrett ND, Barrett ADT (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828","journal-title":"J Virol"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1073\/pnas.0832193100","volume":"100","author":"Y Modis","year":"2003","unstructured":"Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100:6986","journal-title":"Proc Natl Acad Sci USA"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00018-010-0357-z","volume":"67","author":"IA Rodenhuis-Zybert","year":"2010","unstructured":"Rodenhuis-Zybert IA, Wilschut J, Smit JM (2010) Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci 67:2773","journal-title":"Cell Mol Life Sci"},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/v12040367","volume":"12","author":"MI Anasir","year":"2020","unstructured":"Anasir MI, Ramanathan B, Poh CL (2020) Structure-based design of antivirals against envelope glycoprotein of dengue virus. Viruses 12:367","journal-title":"Viruses"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrmicro1067","volume":"3","author":"S Mukhopadhyay","year":"2005","unstructured":"Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3:13","journal-title":"Nat Rev Microbiol"},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/v6010069","volume":"6","author":"M Perera-Lecoin","year":"2013","unstructured":"Perera-Lecoin M, Meertens L, Carnec X, Amara A (2013) Flavivirus entry receptors: an update. Viruses 6:69","journal-title":"Viruses"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.virol.2013.03.011","volume":"441","author":"JT Roehrig","year":"2013","unstructured":"Roehrig JT, Butrapet S, Liss NM, Bennett SL, Luy BE, Childers T, Boroughs KL, Stovall JL, Calvert AE, Blair CD, Huang CY-H (2013) Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in vero cells prior to membrane fusion. Virology 441:114","journal-title":"Virology"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/viro.1998.9200","volume":"246","author":"JT Roehrig","year":"1998","unstructured":"Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317","journal-title":"Virology"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.virol.2007.05.042","volume":"366","author":"GD Gromowski","year":"2007","unstructured":"Gromowski GD, Barrett ADT (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349","journal-title":"Virology"},{"key":"726_CR21","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1099\/0022-1317-82-8-1885","volume":"82","author":"P Thullier","year":"2001","unstructured":"Thullier P, Demangel C, Bedouelle H, M\u00e9gret F, Jouan A, Deubel V, Mazi\u00e9 J-C, Lafaye P (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82:1885","journal-title":"J Gen Virol"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1128\/JVI.06871-11","volume":"86","author":"WM Wahala","year":"2012","unstructured":"Wahala WM, Claire H, Siritorn B, White LJ, de Silva AM (2012) Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86:4019","journal-title":"J Virol"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1128\/JVI.00432-07","volume":"81","author":"S Sukupolvi-Petty","year":"2007","unstructured":"Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816","journal-title":"J Virol"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cell.2005.11.042","volume":"124","author":"E Pokidysheva","year":"2006","unstructured":"Pokidysheva E, Zhang Y, Battisti J, Bator C, Chipman P, Xiao C, Gregorio GG, Hendrickson W, Kuhn R, Rossmann M (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124:485","journal-title":"Cell"},{"key":"726_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.antiviral.2012.10.007","volume":"96","author":"MMF Alen","year":"2012","unstructured":"Alen MMF, Dallmeier K, Balzarini J, Neyts J, Schols D (2012) Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. Antiviral Res 96:280","journal-title":"Antiviral Res"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature02165","volume":"427","author":"Y Modis","year":"2004","unstructured":"Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313","journal-title":"Nature"},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1128\/JVI.02957-12","volume":"87","author":"DE Klein","year":"2013","unstructured":"Klein DE, Choi JL, Harrison SC (2013) Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol 87:2287","journal-title":"J Virol"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1128\/JVI.00170-10","volume":"84","author":"M Liao","year":"2010","unstructured":"Liao M, S\u00e1nchez-San Mart\u00edn C, Zheng A, Kielian M (2010) In Vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein. J Virol 84:5730","journal-title":"J Virol"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"e00804-16","DOI":"10.1128\/mBio.00804-16","volume":"7","author":"LA Byk","year":"2016","unstructured":"Byk LA, Iglesias NG, De Maio FA, Gebhard LG, Rossi M, Gamarnik AV (2016) Dengue virus genome uncoating requires ubiquitination. MBio 7:e00804-16","journal-title":"MBio"},{"key":"726_CR30","doi-asserted-by":"publisher","first-page":"e01766-17","DOI":"10.1128\/JVI.01766-17","volume":"92","author":"DW Reid","year":"2018","unstructured":"Reid DW, Campos RK, Child JR, Zheng T, Chan KWK, Bradrick SS, Vasudevan SG, Garcia-Blanco MA, Nicchitta CV (2018) Dengue virus selectively annexes endoplasmic reticulum-associated translation machinery as a strategy for co-opting host cell protein synthesis. J Virol 92:e01766-17","journal-title":"J Virol"},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.mib.2008.06.004","volume":"11","author":"R Perera","year":"2008","unstructured":"Perera R, Kuhn RJ (2008) Structural proteomics of dengue virus. Curr Opin Microbiol 11:369","journal-title":"Curr Opin Microbiol"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41182-016-0004-y","volume":"44","author":"ML Moi","year":"2016","unstructured":"Moi ML, Takasaki T, Kurane I (2016) Human antibody response to dengue virus: implications for dengue vaccine design. Trop Med Health 44:1","journal-title":"Trop Med Health"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/v3122374","volume":"3","author":"WMPB Wahala","year":"2011","unstructured":"Wahala WMPB, de Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3:2374","journal-title":"Viruses"},{"key":"726_CR34","doi-asserted-by":"crossref","unstructured":"Kulkarni R (2020) Antibody-dependent enhancement of viral infections. In: Dynamics of immune activation in viral diseases","DOI":"10.1007\/978-981-15-1045-8_2"},{"key":"726_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/590117","volume":"198","author":"TNB Chau","year":"2008","unstructured":"Chau TNB, Quyen NTH, Thuy TT, Tuan NM, Hoang DM, Dung NTP, Lien LB, Quy NT, Hieu NT, Hieu LTM, Hien TT, Hung NT, Farrar J, Simmons CP (2008) Dengue in Vietnamese infants-results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198:516","journal-title":"J Infect Dis"},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1086\/648407","volume":"200","author":"TNB Chau","year":"2009","unstructured":"Chau TNB, Hieu NT, Anders KL, Wolbers M, Lien LB, Hieu LTM, Hien TT, Hung NT, Farrar J, Whitehead S, Simmons CP (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200:1893","journal-title":"J Infect Dis"},{"key":"726_CR37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3389\/fmicb.2019.00738","volume":"10","author":"MI Anasir","year":"2019","unstructured":"Anasir MI, Poh CL (2019) Structural vaccinology for viral vaccine design. Front Microbiol 10:738","journal-title":"Front Microbiol"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1073\/pnas.0703498104","volume":"104","author":"AP Goncalvez","year":"2007","unstructured":"Goncalvez AP, Engle RE, St-Claire M, Purcell RH, Lai C-J (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104:9422","journal-title":"Proc Natl Acad Sci USA"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E (2017) Antibody-dependent enhancement of severe dengue disease in humans. Science (New York, N.Y.) 358:929","journal-title":"Science (New York, N.Y.)"},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","volume":"212","author":"BD Kirkpatrick","year":"2015","unstructured":"Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS (2015) Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 212:702","journal-title":"J Infect Dis"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/infdis\/jiw067","volume":"214","author":"AP Durbin","year":"2016","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS (2016) A 12-month-interval dosing study in adults indicates that a single dose of the National Institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 214:832","journal-title":"J Infect Dis"},{"key":"726_CR42","doi-asserted-by":"publisher","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","volume":"8","author":"BD Kirkpatrick","year":"2016","unstructured":"Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP (2016) the live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 8:330ra36","journal-title":"Sci Transl Med"},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"e0005584","DOI":"10.1371\/journal.pntd.0005584","volume":"11","author":"SS Whitehead","year":"2017","unstructured":"Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD (2017) In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 11:e0005584","journal-title":"PLoS Negl Trop Dis"},{"key":"726_CR44","doi-asserted-by":"crossref","unstructured":"Kallas EG, Precioso AR, Palacios R, Thom\u00e9 B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da Gra\u00e7a Salom\u00e3o M, da Silva A, Espinola HM, do Prado Santos J, Santos CLS, Timenetsky MCST, Miraglia JL, Gallina NMF, Weiskopf D, Sette A, Goulart R, Salles RT, Maestri A, Sallum AME, Farhat SCL, Sakita NK, Ferreira JCOA, Silveira CGT, Costa PR, Raw I, Whitehead SS, Durbin AP, Kalil J (2020) Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis 20:839","DOI":"10.1016\/S1473-3099(20)30023-2"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","volume":"207","author":"AP Durbin","year":"2013","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS (2013) A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207:957","journal-title":"J Infect Dis"},{"key":"726_CR46","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","volume":"98","author":"JR Danko","year":"2018","unstructured":"Danko JR, Kochel T, Teneza-Mora N, Luke TC, Raviprakash K, Sun P, Simmons M, Moon JE, De La Barrera R, Martinez LJ, Thomas SJ, Kenney RT, Smith L, Porter KR (2018) Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial. Am J Trop Med Hyg 98:849","journal-title":"Am J Trop Med Hyg"},{"key":"726_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","volume":"30","author":"KR Porter","year":"2012","unstructured":"Porter KR, Ewing D, Chen L, Wu S-J, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K (2012) Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 30:336","journal-title":"Vaccine"},{"key":"726_CR48","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","volume":"15","author":"SB Manoff","year":"2019","unstructured":"Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, Roberts CC, Lickliter J, Krishnarajah J, Bett A, Dubey S, Finn T, Coller B-A (2019) Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-na\u00efve adults. Hum Vaccines Immunother 15:2195","journal-title":"Hum Vaccines Immunother"},{"key":"726_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coviro.2020.09.004","volume":"43","author":"A Wilder-Smith","year":"2020","unstructured":"Wilder-Smith A (2020) Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol 43:71","journal-title":"Curr Opin Virol"},{"key":"726_CR50","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41467-021-21384-0","volume":"12","author":"UK Nivarthi","year":"2021","unstructured":"Nivarthi UK, Swanstrom J, Delacruz MJ, Patel B, Durbin AP, Whitehead SS, Kirkpatrick BD, Pierce KK, Diehl SA, Katzelnick L, Baric RS, de Silva AM (2021) A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nat Commun 12:1102","journal-title":"Nat Commun"},{"key":"726_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","volume":"15","author":"JE Osorio","year":"2016","unstructured":"Osorio JE, Wallace D, Stinchcomb DT, Recombinant A (2016) Chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines 15:497","journal-title":"Expert Rev Vaccines"},{"key":"726_CR52","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Ven\u00e2ncio da Cunha R, Jimeno J, L\u00f3pez-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D (2019) Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381:2009","journal-title":"N Engl J Med"},{"key":"726_CR53","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal S, Borja-Tabora C, Martinez Vargas L, Vel\u00e1squez H, Theresa Alera M, Sierra V, Rodriguez-Arenales EJ, Yu D, Wickramasinghe VP, Duarte Moreira EJ, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, L\u00f3pez-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D (2020) Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial. Lancet (London, England) 395:1423","journal-title":"Lancet (London, England)"},{"key":"726_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jbi.2014.11.003","volume":"53","author":"RE Soria-Guerra","year":"2015","unstructured":"Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S (2015) An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform 53:405","journal-title":"J Biomed Inform"},{"key":"726_CR55","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1074\/mcp.M112.020800","volume":"11","author":"S Buus","year":"2012","unstructured":"Buus S, Rockberg J, Forsstr\u00f6m B, Nilsson P, Uhlen M, Schafer-Nielsen C (2012) High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays. Mol Cell Proteom MCP 11:1790","journal-title":"Mol Cell Proteom MCP"},{"key":"726_CR56","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1038\/s41598-017-09199-w","volume":"7","author":"M Ali","year":"2017","unstructured":"Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK (2017) Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep 7:9232","journal-title":"Sci Rep"},{"key":"726_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jtbi.2018.10.005","volume":"459","author":"RA Tahir","year":"2018","unstructured":"Tahir RA, Wu H, Rizwan MA, Jafar TH, Saleem S, Sehgal SA (2018) Immunoinformatics and molecular docking studies reveal potential epitope-based peptide vaccine against DENV-NS3 protein. J Theor Biol 459:162","journal-title":"J Theor Biol"},{"key":"726_CR58","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1016\/j.vaccine.2011.03.002","volume":"29","author":"S Li","year":"2011","unstructured":"Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, Cao H (2011) Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 29:3695","journal-title":"Vaccine"},{"key":"726_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.virusres.2010.07.014","volume":"153","author":"G S\u00e1nchez-Burgos","year":"2010","unstructured":"S\u00e1nchez-Burgos G, Ramos-Casta\u00f1eda J, Cedillo-Rivera R, Dumonteil E (2010) Immunogenicity of novel dengue virus epitopes identified by bioinformatic analysis. Virus Res 153:113","journal-title":"Virus Res"},{"key":"726_CR60","first-page":"587","volume":"144","author":"K Muthusamy","year":"2016","unstructured":"Muthusamy K, Gopinath K, Nandhini D (2016) Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination. Indian J Med Res 144:587","journal-title":"Indian J Med Res"},{"key":"726_CR61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/vaccines8030417","volume":"8","author":"Y Chan","year":"2020","unstructured":"Chan Y, Jazayeri SD, Ramanathan B, Poh CL (2020) Enhancement of tetravalent immune responses to highly conserved epitopes of a dengue peptide vaccine conjugated to polystyrene nanoparticles. Vaccines 8:417","journal-title":"Vaccines"},{"key":"726_CR62","doi-asserted-by":"publisher","first-page":"e52384","DOI":"10.7554\/eLife.52384","volume":"8","author":"ND Durham","year":"2019","unstructured":"Durham ND, Agrawal A, Waltari E, Croote D, Zanini F, Fouch M, Davidson E, Smith O, Carabajal E, Pak JE, Doranz BJ, Robinson M, Sanz AM, Albornoz LL, Rosso F, Einav S, Quake SR, McCutcheon KM, Goo L (2019) Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. Elife 8:e52384","journal-title":"Elife"},{"key":"726_CR63","doi-asserted-by":"publisher","first-page":"e16059","DOI":"10.1371\/journal.pone.0016059","volume":"6","author":"Y-Q Deng","year":"2011","unstructured":"Deng Y-Q, Dai J-X, Ji G-H, Jiang T, Wang H-J, Yang H, Tan W-L, Liu R, Yu M, Ge B-X, Zhu Q-Y, Qin E-D, Guo Y-J, Qin C-F (2011) A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS ONE 6:e16059","journal-title":"PLoS ONE"},{"key":"726_CR64","doi-asserted-by":"publisher","first-page":"11800","DOI":"10.1128\/JVI.05237-11","volume":"85","author":"IA Rodenhuis-Zybert","year":"2011","unstructured":"Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-Metselaar H, Diamond MS, Wilschut J, Smit JM (2011) A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol 85:11800","journal-title":"J Virol"},{"key":"726_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.str.2017.11.017","volume":"26","author":"J Li","year":"2018","unstructured":"Li J, Watterson D, Chang C-W, Che X-Y, Li X-Q, Ericsson DJ, Qiu L-W, Cai J-P, Chen J, Fry SR, Cheung STM, Cooper MA, Young PR, Kobe B (2018) Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope. Structure (London, England: 1993) 26:51","journal-title":"Structure (London, England: 1993)"},{"key":"726_CR66","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.str.2012.01.001","volume":"20","author":"JJB Cockburn","year":"2012","unstructured":"Cockburn JJB, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA (2012) Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure (London, England: 1993) 20:303","journal-title":"Structure (London, England: 1993)"},{"key":"726_CR67","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.4049\/jimmunol.1200227","volume":"188","author":"CM Midgley","year":"2012","unstructured":"Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, Screaton GR (2012) Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol (Baltimore, Md: 1950) 188:4971","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"726_CR68","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41590-018-0227-7","volume":"19","author":"M Renner","year":"2018","unstructured":"Renner M, Flanagan A, Dejnirattisai W, Puttikhunt C, Kasinrerk W, Supasa P, Wongwiwat W, Chawansuntati K, Duangchinda T, Cowper A, Midgley CM, Malasit P, Huiskonen JT, Mongkolsapaya J, Screaton GR, Grimes JM (2018) Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Nat Immunol 19:1248","journal-title":"Nat Immunol"},{"key":"726_CR69","doi-asserted-by":"publisher","first-page":"15411","DOI":"10.1038\/ncomms15411","volume":"8","author":"A Rouvinski","year":"2017","unstructured":"Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney M-C, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, Mongkolsapaya J, Rey FA, Screaton GR (2017) Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat Commun 8:15411","journal-title":"Nat Commun"},{"key":"726_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney M-C, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despr\u00e8s P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA (2015) Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109","journal-title":"Nature"},{"key":"726_CR71","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","volume":"169","author":"DF Robbiani","year":"2017","unstructured":"Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, Azzopardi SA, Uhl LFK, Saeed M, Sevilla-Reyes EE, Agudelo M, Yao K-H, Golijanin J, Gristick HB, Lee YE, Hurley A, Caskey M, Pai J, Oliveira T, Wunder EAJ, Sacramento G, Nery NJ, Orge C, Costa F, Reis MG, Thomas NM, Eisenreich T, Weinberger DM, de Almeida ARP, West APJ, Rice CM, Bjorkman PJ, Reyes-Teran G, Ko AI, MacDonald MR, Nussenzweig MC (2017) Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169:597","journal-title":"Cell"},{"key":"726_CR72","doi-asserted-by":"publisher","first-page":"e1002930","DOI":"10.1371\/journal.ppat.1002930","volume":"8","author":"SK Austin","year":"2012","unstructured":"Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH (2012) Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8:e1002930","journal-title":"PLoS Pathog"},{"key":"726_CR73","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/emboj.2011.439","volume":"31","author":"JJB Cockburn","year":"2012","unstructured":"Cockburn JJB, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerroy S, Dussart P, Chernomordik LV, Lai C-J, Rey FA (2012) Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J 31:767","journal-title":"EMBO J"},{"key":"726_CR74","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nsmb.1382","volume":"15","author":"S-M Lok","year":"2008","unstructured":"Lok S-M, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15:312","journal-title":"Nat Struct Mol Biol"},{"key":"726_CR75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12985-017-0856-8","volume":"14","author":"W-H Chen","year":"2017","unstructured":"Chen W-H, Chou F-P, Wang Y-K, Huang S-C, Cheng C-H, Wu T-K (2017) Characterization and epitope mapping of dengue virus type 1 specific monoclonal antibodies. Virology Journal 14:189","journal-title":"Virology Journal"},{"key":"726_CR76","doi-asserted-by":"publisher","first-page":"e1004072","DOI":"10.1371\/journal.ppat.1004072","volume":"10","author":"MA Edeling","year":"2014","unstructured":"Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH (2014) Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog 10:e1004072","journal-title":"PLoS Pathog"},{"key":"726_CR77","doi-asserted-by":"publisher","first-page":"46007","DOI":"10.1074\/jbc.M307776200","volume":"278","author":"K-P Wu","year":"2003","unstructured":"Wu K-P, Wu C-W, Tsao Y-P, Kuo T-W, Lou Y-C, Lin C-W, Wu S-C, Cheng J-W (2003) Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem 278:46007","journal-title":"J Biol Chem"},{"key":"726_CR78","doi-asserted-by":"publisher","first-page":"38755","DOI":"10.1074\/jbc.M402385200","volume":"279","author":"DE Volk","year":"2004","unstructured":"Volk DE, Beasley DWC, Kallick DA, Holbrook MR, Barrett ADT, Gorenstein DG (2004) solution structure and antibody binding studies of the envelope protein domain III from the New York Strain of West Nile Virus. J Biol Chem 279:38755","journal-title":"J Biol Chem"},{"key":"726_CR79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.antiviral.2018.04.018","volume":"155","author":"X Cui","year":"2018","unstructured":"Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J (2018) Peptides P4 and P7 derived from e protein inhibit entry of dengue virus serotype 2 via interacting with \u03923 integrin. Antivir Res 155:20","journal-title":"Antivir Res"},{"key":"726_CR80","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1128\/JVI.06871-11","volume":"86","author":"WMPB Wahala","year":"2012","unstructured":"Wahala WMPB, Huang C, Butrapet S, White LJ, de Silva AM (2012) Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86:4019","journal-title":"J Virol"},{"key":"726_CR81","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","volume":"392","author":"WMPB Wahala","year":"2009","unstructured":"Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103","journal-title":"Virology"},{"key":"726_CR82","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.celrep.2018.10.031","volume":"25","author":"JR Keeffe","year":"2018","unstructured":"Keeffe JR, Van Rompay KKA, Olsen PC, Wang Q, Gazumyan A, Azzopardi SA, Schaefer-Babajew D, Lee YE, Stuart JB, Singapuri A, Watanabe J, Usachenko J, Ardeshir A, Saeed M, Agudelo M, Eisenreich T, Bournazos S, Oliveira TY, Rice CM, Coffey LL, MacDonald MR, Bjorkman PJ, Nussenzweig MC, Robbiani DF (2018) A combination of two human monoclonal antibodies prevents Zika virus escape mutations in non-human primates. Cell Rep 25:1385","journal-title":"Cell Rep"},{"key":"726_CR83","doi-asserted-by":"publisher","first-page":"e1000823","DOI":"10.1371\/journal.ppat.1000823","volume":"6","author":"B Shrestha","year":"2010","unstructured":"Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O\u2019Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823","journal-title":"PLoS Pathog"},{"key":"726_CR84","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1128\/JVI.78.9.4665-4674.2004","volume":"78","author":"R Men","year":"2004","unstructured":"Men R, Yamashiro T, Goncalvez AP, Wernly C, Schofield DJ, Emerson SU, Purcell RH, Lai C-J (2004) Identification of chimpanzee fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78:4665","journal-title":"J Virol"},{"key":"726_CR85","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1073\/pnas.1200566109","volume":"109","author":"R de Alwis","year":"2012","unstructured":"de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WMPB, White LJ, Diamond MS, Baric RS, Crowe JEJ, de Silva AM (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439","journal-title":"Proc Natl Acad Sci USA"},{"key":"726_CR86","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/emmm.201303404","volume":"6","author":"G Fibriansah","year":"2014","unstructured":"Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng T-S, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JEJ, Lok S-M (2014) A potent anti-dengue human antibody preferentially recognizes the conformation of e protein monomers assembled on the virus surface. EMBO Mol Med 6:358","journal-title":"EMBO Mol Med"},{"key":"726_CR87","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","volume":"349","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah G, Ibarra KD, Ng T-S, Smith SA, Tan JL, Lim X-N, Ooi JSG, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JEJ, Lok S-M (2015) Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking e protein dimers. Science (New York, N.Y.) 349:88","journal-title":"Science (New York, N.Y.)"},{"key":"726_CR88","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1038\/ncomms7341","volume":"6","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng T-S, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok S-M (2015) A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341","journal-title":"Nat Commun"},{"key":"726_CR89","doi-asserted-by":"publisher","first-page":"139ra83","DOI":"10.1126\/scitranslmed.3003888","volume":"4","author":"EP Teoh","year":"2012","unstructured":"Teoh EP, Kukkaro P, Teo EW, Lim APC, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KGC, Chan AHY, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JKW, Ng ML, Alonso S, Fisher D, Shi P-Y, Hanson BJ, Lok S-M, MacAry PA (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra83","journal-title":"Sci Transl Med"},{"key":"726_CR90","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1099\/vir.0.055178-0","volume":"94","author":"X-Q Li","year":"2013","unstructured":"Li X-Q, Qiu L-W, Chen Y, Wen K, Cai J-P, Chen J, Pan Y-X, Li J, Hu D-M, Huang Y-F, Liu L-D, Ding X-X, Guo Y-H, Che X-Y (2013) Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. J Gen Virol 94:2191","journal-title":"J Gen Virol"},{"key":"726_CR91","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","volume":"16","author":"W Dejnirattisai","year":"2015","unstructured":"Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, Grimes JM, Tsai W-Y, Lai C-Y, Wang W-K, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR (2015) A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170","journal-title":"Nat Immunol"},{"key":"726_CR92","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.1128\/JVI.01874-13","volume":"87","author":"A Yamanaka","year":"2013","unstructured":"Yamanaka A, Kotaki T, Konishi E (2013) A mouse monoclonal antibody against dengue virus type 1 mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol 87:12828","journal-title":"J Virol"},{"key":"726_CR93","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0168-1656(99)00037-1","volume":"69","author":"P Thullier","year":"1999","unstructured":"Thullier P, Lafaye P, M\u00e9gret F, Deubel V, Jouan A, Mazi\u00e9 JC (1999) A recombinant fab neutralizes dengue virus in vitro. J Biotechnol 69:183","journal-title":"J Biotechnol"},{"key":"726_CR94","doi-asserted-by":"publisher","first-page":"2680160","DOI":"10.1155\/2017\/2680160","volume":"2017","author":"JL Sanchez-Trincado","year":"2017","unstructured":"Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA (2017) Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res 2017:2680160","journal-title":"J Immunol Res"},{"key":"726_CR95","doi-asserted-by":"publisher","first-page":"e1007716","DOI":"10.1371\/journal.ppat.1007716","volume":"15","author":"L Li","year":"2019","unstructured":"Li L, Meng W, Horton M, DiStefano DR, Thoryk EA, Pfaff JM, Wang Q, Salazar GT, Barnes T, Doranz BJ, Bett AJ, Casimiro DR, Vora KA, An Z, Zhang N (2019) Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes. PLoS Pathog 15:e1007716","journal-title":"PLoS Pathog"},{"key":"726_CR96","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41541-016-0003-3","volume":"2","author":"M Xu","year":"2017","unstructured":"Xu M, Zuest R, Velumani S, Tukijan F, Toh YX, Appanna R, Tan EY, Cerny D, MacAry P, Wang C-I, Fink K (2017) A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. NPJ Vaccines 2:2","journal-title":"NPJ Vaccines"},{"key":"726_CR97","doi-asserted-by":"publisher","first-page":"e1007836","DOI":"10.1371\/journal.ppat.1007836","volume":"15","author":"D Hu","year":"2019","unstructured":"Hu D, Zhu Z, Li S, Deng Y, Wu Y, Zhang N, Puri V, Wang C, Zou P, Lei C, Tian X, Wang Y, Zhao Q, Li W, Prabakaran P, Feng Y, Cardosa J, Qin C, Zhou X, Dimitrov DS, Ying T (2019) A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathog 15:e1007836","journal-title":"PLoS Pathog"},{"key":"726_CR98","doi-asserted-by":"publisher","first-page":"e4021","DOI":"10.7717\/peerj.4021","volume":"5","author":"S Injampa","year":"2017","unstructured":"Injampa S, Muenngern N, Pipattanaboon C, Benjathummarak S, Boonha K, Hananantachai H, Wongwit W, Ramasoota P, Pitaksajjakul P (2017) Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity. PeerJ 5:e4021","journal-title":"PeerJ"},{"key":"726_CR99","doi-asserted-by":"publisher","first-page":"e00873","DOI":"10.1128\/mBio.00873-13","volume":"4","author":"SA Smith","year":"2013","unstructured":"Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JEJ (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the Bc loop of domain II of the envelope protein. MBio 4:e00873","journal-title":"MBio"},{"key":"726_CR100","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.4269\/ajtmh.16-0319","volume":"95","author":"M Simmons","year":"2016","unstructured":"Simmons M, Putnak R, Sun P, Burgess T, Marasco WA (2016) Antibody prophylaxis against dengue virus 2 infection in non-human primates. Am J Trop Med Hyg 95:1148","journal-title":"Am J Trop Med Hyg"},{"key":"726_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.antiviral.2017.05.007","volume":"144","author":"EZ Ong","year":"2017","unstructured":"Ong EZ, Budigi Y, Tan HC, Robinson LN, Rowley KJ, Winnett A, Hobbie S, Shriver Z, Babcock GJ, Ooi EE (2017) Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates. Antivir Res 144:44","journal-title":"Antivir Res"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-021-00726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00430-021-00726-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-021-00726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T09:09:40Z","timestamp":1676106580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00430-021-00726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s00430-021-00726-1","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}